Document is current
Any future updates will be listed below
-
Authors
Dansson, Hákon Valur
Stempfle, Lena http://orcid.org/0000-0002-6580-3942
Egilsdóttir, Hildur
Schliep, Alexander
Portelius, Erik
Blennow, Kaj
Zetterberg, Henrik
Johansson, Fredrik D.
,
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2017-00915)
Alzheimer's Drug Discovery Foundation (RDAPB-201809-2016615)
Swedish Alzheimer's Association (AF-742881)
Hj\"{a}rnfonden (FO2017-0243)
Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (ALFGBG-715986)
EU Joint Programme - Neurodegenerative Disease Research (JPND2019-466-236)
Vetenskapsrådet (2018-02532)
European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862)
AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C)
Familjen Erling-Perssons Stiftelse
Hj\"{a}rnfonden (FO2019-0228)
Olav Thon Foundation
European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement (860197 MIRIADE)
UK Dementia Research Institute at UCL
Knut och Alice Wallenbergs Stiftelse
Knut och Alice Wallenbergs Stiftelse
Chalmers Tekniska H\"{o}gskola (#CHAIR-CO-AIMDAD-2020-012-1)
Chalmers University of Technology
- License Information
-
More Information
Article History
Received: 1 March 2021
Accepted: 8 August 2021
First Online: 6 September 2021
Declarations
:
: All procedures were approved by the Institutional Review Boards of all participating institutions. Written informed consent was obtained from every research participant according to the Declaration of Helsinki and the Belmont Report.
: Not applicable.
: KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other authors declare that they have no competing interests.
